A double-blind trial of adjunctive allopurinol for schizophrenia

Schizophrenia Research

Volumn 109, Issue 1-3, 2009, Pages 66-69

  Dickerson, Faith B ^a   Stallings, Cassie R ^a   Origoni, Andrea E ^a   Sullens, Anne ^a   Khushalani, Sunil ^a   Sandson, Neil ^a   Yolken, Robert H ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allopunirol; Clinical trial; Schizophrenia

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LITHIUM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUTROPENIA; PNEUMONIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCHIZOPHRENIA; SKIN DISEASE; TOOTH DISEASE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT DISEASE;

ADULT; ALLOPURINOL; AMBULATORY CARE; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 62649140849     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.12.028     Document Type: Article

References (14)

1. Akhondzadeh S., Safarcherat i.A., and Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry. 29 2 (2005) 253-259
2. Brunstein M.G., Ghisolfi E.S., Ramos F.L., and Lara D.R. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J. Clin. Psychiatry. 66 2 (2005) 213-219
3. Buie L.W., Oertel M.D., and Cala S.O. Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia. Ann. Pharmacother. 40 12 (2006) 2200-2204
4. Cuzick J. A Wilcoxon type test for trend. Stat. Med. 4 1 (1985) 87-90
5. El-Farrash M.A., Youssef J.M., and El-Mongy S.E. Allopurinol as a potential therapeutic agent for recurrent herpes labialis. J. Med. Dent. Sci. 50 2 (2003) 147-154
6. Kay S.R., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization. J. Psychiatry-Suppl. 7 (1989) 59-67
7. Lara D.R., Belmonte-de-Abreu P., and Souza D.O. Allopurinol for refractory aggression and self-inflicted behaviour. J. Psychopharmacol. 1 (2000) 81-83
8. Lara D.R., Brunstein M.G., Ghisolfi E.S., Lobato M.I., Belmonte-de-Abreu P., and Souza D.O. Allopurinol augmentation for poorly responsive schizophrenia. Int. Clin. Psychopharmacol. 4 (2001) 235-237
9. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., and Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry. 30 4 (2006) 617-629
10. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., Green-Paden L.D., Tenhula W.N., Boerescu D., Tek C., Sandson N., and Steinwachs D.M. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr. Bull. 30 2 (2004) 193-217
11. Manna L., Vitale F., Reale S., Picillo E., Neglia G., Vescio F., and Gravino A.E. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet. J. (2008) Sep 23
12. Namazi M.R. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int. Immunopharmacol. 4 3 (2004) 349-353
13. Pea F. Pharmacology of drugs for hyperuricemia. In: Roneco A., and Rodeghiero F. (Eds). Hyperuricemic Syndromes. Pathophysiology and Therapy. Contrib Nephrol. Karger, Basel vol. 147 (2005) 35-46
14. Randolph C. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (1998), Psychological Corporation, San Antonio, TX.